JohnTHammMD

Oncology • Louisville, KY

Physician

Join to view full profile

Are you Dr. Hamm?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 66 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
315 E Broadway
Louisville, KY 40202
Phone+1 502-629-2500

Fax+1 502-629-3166
Is this information wrong?

Summary

Dr. John Hamm, MD is an oncologist in Louisville, Kentucky. He is currently licensed to practice medicine in Kentucky and Indiana. He is affiliated with Norton Children's Hospital, UofL Health - Jewish Hospital, and Norton Hospital.

Education & Training

University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 1985 - 1987
University of Louisville School of MedicineResidency, Internal Medicine, 1982 - 1985
Vanderbilt University School of MedicineClass of 1982

Certifications & Licensure

KY State Medical License 1983 - 2025
IN State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
Unknown status
Phase 3
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Unknown status
Phase 3
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Unknown status
Phase 1, Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Start of enrollment: 2019 May 14
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomize...
Caicun Zhou, Minu K Srivastava, Hao Xu, Enriqueta Felip, Heather Wakelee, Nasser Altorki, Martin Reck, Rüdiger Liersch, Anna Kryzhanivska, Satoshi Oizumi, Hiroshi Tana...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
4 citations
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B Mettu, Pierre L Triozzi, John Hamm, Gongfu Zhou, ...> ;Cancer. 2023 Jan 1
35 citations
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Christina I Tsien, Stephanie L Pugh, Adam P Dicker, Jeffrey J Raizer, Martha M Matuszak, Enrico C Lallana, Jiayi Huang, Ozer Algan, Nimisha Deb, Lorraine Portelance, J...> ;Journal of Clinical Oncology. 2023 Feb 20
25 citations
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma
Conor H. O’Neill, Traci Hayat, John T. Hamm, Mary Healey, Qianqian Zheng, Yan Li, Robert C. G. Martin> ;Surgery. 2020 Jul 4
1 citations
International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification
Douglas W. Blayney, Nafisa Albdelhafeez, Abdul Rahman Jazieh, Carlos Frederico Pinto, Adrian Udrea, Alex Roach, Devika Govind Das, Stephen Grubbs, John Hamm, Mohammad ...> ;JCO Global Oncology. 2020 May 6
4 citations
The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer
Sarah E Quinn, Catherine E Crandell, Morgan E Blake, Amy M Bontrager, Alexandra G Dempsey, Derek J Lewis, John T. Hamm, Joseph M Flynn, Grant S. Smith, Christopher J W...> ;Physical Therapy. 2020 Mar 10
5 citations
Phase II trial of carfilzomib plus irinotecan in patients with small-cell lung cancer who have progressed on prior platinum-based chemotherapy
Susanne M. Arnold, Kari Chansky, Maria Q. Baggstrom, Michael A. Thompson, Rachel E. Sanborn, John L. Villano, Saiama N. Waqar, John T. Hamm, Markos Leggas, Maurice Wil...> ;Clinical Lung Cancer. 2020 Jan 27
91 citations
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Jared Weiss, Tibor Csoszi, M. Maglakelidze, Robert Hoyer, J.T. Beck, M. Domine Gomez, A. Lowczak, Raid Aljumaily, C.M. Rocha Lima, Ralph V. Boccia, Wahid Hanna, Petros...> ;Annals of Oncology. 2019 Oct 1
4 citations
Multidisciplinary approach to low-dose CT screening for lung cancer in a metropolitan community
Lisa B E Shields, Jessica G Wilkett Barnes, Connie Buckley, George J Mikos, Katie N Rogers, John T. Hamm, Joseph M Flynn, Steven T. Hester, Joshua T. Honaker> ;Family Practice. 2019 Jul 4
28 citations
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazin...
Robin L. Jones, George D. Demetri, Scott M. Schuetze, Mohammed M. Milhem, Anthony D. Elias, B.A. Van Tine, John T. Hamm, Sharon Anne McCarthy, George Wang, Trilok V. P...> ;Annals of Oncology. 2018 Sep 1
8 citations
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (On...
Susanne M. Arnold, Kari Chansky, Markos Leggas, Michael A. Thompson, John L. Villano, John T. Hamm, Rachel E. Sanborn, Glen J. Weiss, Gurkamal Chatta, Maria Q. Baggstrom> ;Investigational New Drugs. 2017 Feb 16
Metacognition, social cognition, and symptoms in patients with first episode and prolonged psychoses.
Vohs, J. L.,Lysaker, P. H.,Francis, M. M.,Hamm, J.,Buck, K. D.,Olesek, K.,Outcalt, J.,Dimaggio, G.,Leonhardt, B.,Liffick, E.,Mehdiyoun, N.,Breier, A.> ;Schizophr. Res.. 2014 Feb 08
48 citations
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study
Ahmad Awada, Agustin A. Garcia, Stephen Chan, Guy Jerusalem, Robert E. Coleman, M.T. Huizing, A Mehdi, Sue M O'Reilly, John T. Hamm, Peter Barrett-Lee, Veronique Cocqu...> ;The Lancet. Oncology. 2013 Nov 1
34 citations
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William Jeffery Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz Malik, Thomas A. Rado, Philip J. McGee, Donald A....> ;Cancer. 2013 Jul 15
100 citations
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide ex...
Brian L. Samuels, Shanta Chawla, Shreyaskumar Patel, M. von Mehren, John T. Hamm, Pamela E. Kaiser, Scott M. Schuetze, J. Li, A. Aymes, George D. Demetri> ;Annals of Oncology. 2013 Jun 1
40 citations
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Gayle S. Jameson, John T. Hamm, Glen J. Weiss, Carlos Alemany, Stephen P. Anthony, Michele Basche, Ramesh K. Ramanathan, Mitesh J. Borad, Raoul Tibes, Allen Lee Cohn, ...> ;Clinical Cancer Research. 2013 Jan 1
Molecular targeting in cancer therapy: can we fulfill the promise?
John T. Hamm> ;Oncology. 2012 Nov 16
A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.
Richards DA, Stephenson J, Wolpin BM, Becerra C, Hamm JT, Messersmith WA, Devens S, Cushing J, Schmalbach T, Fuchs CS> ;J. Clin. Oncol.. 2012-02-01
14 citations
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Radj Gervais, John D. Hainsworth, Normand Blais, Benjamin Besse, Janessa Laskin, John T. Hamm, Allan Lipton, Kathy S. Albain, Gregory A. Masters, Ronald B. Natale, Pau...> ;Lung Cancer. 2011 Dec 1
Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant an...
Garcia A, Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Brown M, Zhao C, Hanna...> ;J. Clin. Oncol.. 2011-09-20
The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.
Stephenson J, Richards DA, Wolpin BM, Becerra C, Hamm JT, Messersmith WA, Devens S, Cushing J, Goddard J, Schmalbach T, Fuchs CS> ;J. Clin. Oncol.. 2011-05-20
Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).
Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Brown M, Zhao C, Hannah AL, Masu...> ;J. Clin. Oncol.. 2011-05-20
A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).
Infante JR, Cohn AL, Reid TR, Edenfield WJ, Cescon T, Hamm JT, Tarazi JC, Kim S, Rosbrook B, Cartwright TH> ;J. Clin. Oncol.. 2011-02-01
53 citations
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
John Nemunaitis, Gary L. Clayman, Sanjiv S. Agarwala, William J. M. Hrushesky, James R. Wells, Charles E. Moore, John T. Hamm, George H. Yoo, José Baselga, Barbara A. ...> ;Clinical Cancer Research. 2009 Dec 15
13 citations
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
Elena G. Chiorean, Tomislav Dragovich, John Hamm, Carlos Barrios, Carlos F. Gorini, V. K. Langmuir, Stewart Kroll, Donald Jung, George T. Tidmarsh, Patrick J. Loehrer> ;American Journal of Clinical Oncology. 2009 Aug 1
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

UofL Health - Jewish HospitalLouisville, Kentucky
Norton HospitalLouisville, Kentucky
Norton Children's HospitalLouisville, Kentucky
UofL Health - UofL HospitalLouisville, Kentucky